cm082

Mucosal Melanoma

AnewPharmaPhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

33 Active assets in the Mucosal Melanoma cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Melanoma Institute Australia	Phase 3	BB
Tyrosinase Peptide University of Southern California	Phase 3	BB
INTERFERON ALFA-2B Shanghai Junshi Bioscience Co., Ltd.	Phase 3	B
Ifa Craig L Slingluff, Jr	Phase 2	B
Carboplatin Sun Yat-sen University	Phase 3	B

View all 50 →

Same molecule, other indications

cm082 is also rated in:

renal cell carcinomaDormant

BB

Indicative ·

66 / 100

small cell lung carcinomaDormant

CCC

Indicative ·

48 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.